Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour
Authors:
M. Kolečková 1; T. Tichý 1; B. Melichar 2; L. Veverková 3
; O. Hes 4; V. Kolek 5; Z. Kolář 1
Published in the journal:
Klin Onkol 2019; 32(Supplementum1): 154-156
Category:
Článek ve sborníku
Summary
Background: Clear cell renal carcinoma (ccRC) accounts for 65–70% of renal carcinomas with peak occurrence at the 6th and 7th age decade, predominantly in males. At the time of diagnosis, especially pulmonary metastases can be found in one-third of patients. There have also been described as late metastases for several decades after nephrectomy. In our case report, clinical course indicated primary lung tumour. Histological differential diagnosis included malignant pleural mesothelioma, lung adenocarcinoma and squamous cell carcinoma with clear cell differentiation or primary clear cell adenocarcinoma of the lung. However, using immunohistochemistry, all these possible diagnoses were excluded.
Case report: We present a case of 62-year old man with 3 months history of progressive dyspnea accompanied with a cough and recurrent pleural effusions. PET/CT scan revealed metastatic tumour spread with right-sided pleural thickening, multiple pulmonary tumour foci, mediastinal, cervical, abdominal para-aortic and pelvic lymph node involvement and skeletal metastasis. The patient died one day after administration of palliative chemotherapy. The autopsy showed the majority of changes in the right hemithorax, was caused by a diffuse yellowish, extremely tough tumour infiltrating parietal and visceral pleura with adhesions and obliteration of truncus pulmonalis. In left lung and both renal cortices we could see scant nodules, mimicking primary lung tumour metastasis. In close proximity to the left renal hilum we found unusual homogeneous white round to oval tissue of 80 × 86 × 72 mm in diameter, with identical histological pattern. Extensive immunohistochemical profile (positivity of CK18, PAX8, vimentin, androgen receptor, napsin A; negativity of mesothelial markers, TTF-1, CK7, CK20, CDX-2, CD10, PSA, CK34B12 and PAS-D) was compatible with metastatic ccRC.
Conclusion: We present an extremely rare case of morphologically verified metastatic ccRC without evidence of primary lesion in the kidneys. There is speculated the possibility of spontaneous regression of primary tumour. In our case, however, we cannot exclude the possibility of generalized primary tumour of ectopic kidney. This hypothesis is based on the finding of isolated tumour mass adjacent to left renal hilum.
Keywords:
clear cell renal carcinoma – pleural neoplasms – lung cancer – secondary lung tumours – no evidence of primary tumour
Zdroje
1. Bukowski RM. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res 2010; 2: 83–96.
2. Moch H, Amin MB, Argani P et al. Renal cell tumors. In: Moch H, Cubilla AL, Humphrey PA et al (eds). WHO classification of tumours of the urinary system and male genital organs. 4th ed. IARC Press: Lyon 2016: 18–21.
3. McKenney JK. Kidney: Tumors and tumorlike condition. In: Goldblum JR, McKenney JK, Lamps LW et al (eds). Rosai and Ackerman’s surgical pathology. 11th ed. Elsevier Inc.: Philadeplphia 2018: 1025–1040.
4. Beneš P. Metastazující karcinom ledviny – současné možnosti léčby. Klin Farmakol Farm 2010; 24 (1): 38–46.
5. Shiono S, Yoshida J, Nishimura M et al. Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy. Jpn J Clin Oncol 2004; 34 (1): 46–49.
6. Griniatsos J, Michail PO, Menenakos C et al. Metastatic renal clear cell carcinoma mimicking stage IV lung cancer. Int Urol Nephrol 2003; 35 (1): 15–17.
7. Kumar RM, Aziz T, Jamshaid H at al. Metastatic renal cell carcinoma without evidence of a primary renal tumour. Curr Oncol 2014; 21 (3): e521–e524. doi: 10.3747/co.21.1914.
Štítky
Dětská onkologie Chirurgie všeobecná OnkologieČlánek vyšel v časopise
Klinická onkologie
2019 Číslo Supplementum1
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Management pacientů s MPN a neobvyklou kombinací genových přestaveb – systematický přehled a kazuistiky
- Management péče o pacientku s karcinomem ovaria a neočekávanou mutací CDH1 – kazuistika
- Neodolpasse je bezpečný přípravek v krátkodobé léčbě bolesti
- Cinitaprid – v Česku nová účinná látka nejen pro léčbu dysmotilitní dyspepsie
Nejčtenější v tomto čísle
- Metastazující světlobuněčný renální karcinom bez zjevného primárního ložiska v ledvině imitující pokročilé stadium plicní malignity
- Encyklopedie subsetů CLL – unikátní bioinformatický nástroj a databáze pro analýzu subsetů stereotypních B buněčných receptorů u CLL
- Molekulární klasifikace meduloblastomů pomocí celogenomového expresního profilování
- Analýza mikroRNA v krevní plazmě s cílem identifikovat pacienty s duktálním adenokarcinomem pankreatu mající benefit z chirurgické resekce